Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

Rischin D.Harrington K.J.Greil R.Soulières D.Tahara M.de Castro Jr G.Psyrri A.Braña I.Neupane P.Bratland Å.Fuereder T.Hughes B.G.M.Mesía R.Ngamphaiboon N.Rordorf T.Ishak W.Z.W.RUEY-LONG HONGMendoza R.G.Jia L.Chirovsky D.Norquist J.Jin F.Burtness B.2022-10-252022-10-2520221368-8375https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127463915&doi=10.1016%2fj.oraloncology.2022.105815&partnerID=40&md5=0f06abe11d7f301c9d1f879c6200343bhttps://scholars.lib.ntu.edu.tw/handle/123456789/623961[SDGs]SDG3Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048journal article10.1016/j.oraloncology.2022.105815353815762-s2.0-85127463915